Clovis Addresses Some Of The Company’s Biggest Controversies

0 Comments 6 view(s)

Analysts at Leerink maintain an Outperform rating on shares ofClovis Oncology Inc (NASDAQ: CLVS) with a price target boosted from $85 to $114 after the company hosted a conference call on Monday, which addressed some of the biggest controversies it faces.

Latest Ratings for CLVS

Date Firm Action From To
Jun 2017 Janney Capital Upgrades Neutral Buy
Jun 2017 Chardan Capital Upgrades Sell Neutral
Jun 2017 Leerink Swann Initiates Coverage On Outperform

View More Analyst Ratings for CLVS

View the Latest Analyst Ratings

read more